Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study
- 12 April 2011
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 25 (8) , 1354-1356
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Identification of Predictive Markers of Cytarabine Response in AML by Integrative Analysis of Gene-Expression Profiles with Multiple PhenotypesPharmacogenomics, 2011
- The role of FKBP5 in cancer aetiology and chemoresistanceBritish Journal of Cancer, 2010
- Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trialThe Lancet Oncology, 2010
- The Hsp90 Cochaperone, FKBP51, Increases Tau Stability and Polymerizes MicrotubulesThe Journal of Neuroscience, 2010
- Emerging role of FKBP51 in AKT kinase/protein kinase B signalingCell Cycle, 2010
- FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating AktCancer Cell, 2009
- Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell ExpressionCancer Research, 2008
- Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingJournal of the Royal Statistical Society Series B: Statistical Methodology, 1995